Aug. 19 at 5:01 PM
$RIGL I believe Veppanu sales are going to be way more robust than perhaps anticipated. Rigel of course inlicensed Vep this past May (post-approval). This is the first PROTAC and Pfizer of course heavily engaged Key Opinion Leaders. As such, a lot of groundwork is done. When Rigel announced the acquisition they had Dr. Erika Hamilton on the call who is a top KOL in the breast cancer space. She was also the principal investigator of the Phase 3 trial. The pre-launch medical community excitement was strong enough that VEPPANU was already integrated into the National Comprehensive Cancer Network (NCCN) Guidelines right around the time Rigel took control. This means a lot of heavy-lifting was done and it's not like Rigel is educating the market about some new drug no one knows about. This drug is already of interest and the medical community is educated. This was a monster win for Rigel, IMO.
